(Reuters) – BeiGene Ltd said on Tuesday its cancer therapy combination for treating lung cancer in previously untreated patients met the main goal in a late-stage study.
The therapy, tislelizumab, when administered in combination with chemotherapy helped reduce the risk of cancer progression in patients with squamous non-small cell lung cancer.
Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shounak Dasgupta
Our Standards:The Thomson Reuters Trust Principles.
Source news reuters.com, click here to read the full news.
